Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, a gel containing extracts from Coffea arabica and Larrea divaricata was found to significantly thicken eyebrows and eyelashes in most premenopausal and postmenopausal women, without causing adverse effects, but showed no statistical difference from a placebo in overall hair growth.

This study found that a serum combining recombinant growth factors and plant-derived EVs significantly increased eyelash length and density without causing skin hyperpigmentation in healthy female participants over eight weeks.

JAK inhibitors help regrow eyebrow and eyelash hair and improve anxiety and depression in some alopecia areata patients.

The measures for eyebrow and eyelash hair loss in severe Alopecia Areata are reliable and useful for clinical trials.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This study reports that a novel eyelash transplantation method using chalazion forceps effectively thickens and enhances eyelashes by precisely placing transplanted hairs in a narrow recipient area, with approximately 85-92% of transplanted lashes expected to grow within 12 months.

This source highlights the challenges and importance of skilled surgical procedures in eyelash restoration, necessary due to its role in eye protection and aesthetics, while poor outcomes can impact self-esteem and cause ocular issues.

Eyebrow and eyelash hair loss in alopecia areata worsens quality of life.

Topical eyedrops may cause eyelash whitening and skin lightening around the eyes.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

Eyebrow and eyelash regrowth usually matches scalp hair response in alopecia areata patients treated with baricitinib.

In this dermatopathologic examination of an 88-year-old man with progressive eyelash loss and scale on the eyelids, the best diagnosis was suggested as either alopecia areata, alopecia mucinosa, or folliculotropic mycosis.

This study found that among placebo-treated patients in the BRAVE-AA trials, the likelihood of spontaneous hair regrowth in untreated severe alopecia areata was low, with only a small percentage achieving significant scalp, eyebrow, or eyelash hair improvement over 36 weeks.

In this study, a strong positive correlation was found between clinician-reported and patient-reported measures for assessing eyebrow and eyelash hair loss in patients with severe alopecia areata, indicating high agreement during treatment with baricitinib over 52 weeks.

This study aimed to describe the distribution of eyebrow and eyelash hair loss in patients with varying severities of scalp hair loss from alopecia areata but does not report results.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

This study found that some patients with alopecia areata who did not respond to ritlecitinib treatment by Week 24 achieved a positive response with continued therapy by Week 48, with tolerable side effects.

This case report describes a 19-year-old female with systemic lupus erythematosus who exhibited eyelash trichomegaly, a rare disorder involving changes in eyelash characteristics, alongside diffuse alopecia.

This study found that a green tea extract gel was stable across various temperatures, did not cause eye irritation, and significantly increased eyelash growth compared to a placebo after two months of use in human volunteers.

Eyelashes are important for looks and eye protection, and more people are treating sparse eyelashes; more research is needed to understand eyelash biology and improve treatments.

This article examines the morphological and physiological characteristics of eyelash follicles and offers clinical management suggestions for conditions like eyelash loss and trichomegaly, but presents no new clinical results.

This case report describes a rare complication of eyelash transplantation, where it resulted in trichiasis and corneal surface damage, highlighting the need for preoperative counseling about potential ocular risks.

This abstract discusses the FDA approval of Latisse (bimatoprost) for increasing eyelash growth in patients with eyelash hypotrichosis and highlights its efficacy while noting unresolved effectiveness in certain conditions and potential side effects.

Topical latanoprost and bimatoprost ophthalmic solutions don't help eyelash growth in patients with alopecia areata.

In this study, once-daily treatment with bimatoprost 0.03% solution significantly increased eyelash growth, thickness, and darkness in patients with chemotherapy-induced eyelash loss compared to placebo, and was well tolerated over one year.

A single long white eyelash is a rare but benign condition.

This abstract reports no new research findings; it includes an educational image of microorganisms found in a skin biopsy.